ARWR

Arrowhead Pharmaceuticals Inc

64.19

Oct 02 • 3:59 PM ET -0.60 (-0.93%)

64.75

Aftermarket • 7:54 PM ET +0.56 (0.87%)

Healthcare Biotechnology USA Mid NASD

Peers: IONS ALNY BMRN JAZZ ASND CRSP INCY RARE VRTX NBIX

| Held by: VTI IJH VB VBK VXF XMMO XBI MDY IBB IJK

Index	-
Market Cap	9.07B
Enterprise Value	8.84B
Income	-319.95M
Sales	669.50M
Book/sh	3.30
Cash/sh	11.34
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	711
IPO	Dec 16, 1993

P/E	-
Forward P/E	-
PEG	-
P/S	13.54
P/B	19.46
P/C	5.66
P/FCF	-
EV/EBITDA	-
EV/Sales	13.21
Quick Ratio	5.90
Current Ratio	5.90
Debt/Eq	2.96
LT Debt/Eq	2.86
Option/Short	Yes / Yes

EPS (ttm)	-2.24
EPS next Y	-4.80
EPS next Q	-1.55
EPS this Y	-35408.46%
EPS next Y	-35.19%
EPS next 5Y	-
EPS past 3/5Y	80.60% 57.10%
Sales past 3/5Y	50.52% 56.63%
EPS Y/Y TTM	-80.39%
Sales Y/Y TTM	16.85%
EPS Q/Q	-7.51%
Sales Q/Q	171.02%
Earnings	Aug 04 AMC
EPS/Sales Surpr.	-6.52% 70.36%

Insider Own	5.87%
Insider Trans	-0.48%
Inst Own	83.07%
Inst Trans	-2.99%
ROA	-18.32%
ROE	-64.78%
ROIC	-17.81%
Gross Margin	96.15%
Oper. Margin	-33.82%
Profit Margin	-47.79%
SMA20	-10.65%
SMA50	-20.57%
SMA200	-11.45%
Trades

Shs Outstand	141.13M
Shs Float	132.97M
Short Float	6.97%
Short Ratio	4.86
Short Interest	9.27M
52W High	95.49 -32.78%
52W Low	34.47 86.22%
Volatility	2.96% 5.08%
ATR (14)	3.25
RSI (14)	30.08
Beta	1.34
Rel Volume	0.78
Avg Volume	1.91M
Volume	1,487,639

Perf Week	-2.62%
Perf Month	-24.81%
Perf Quarter	-25.83%
Perf Half Y	5.18%
Perf YTD	-3.31%
Perf Year	85.52%
Perf 3Y	144.53%
Perf 5Y	2.54%
Perf 10Y	773.33%
Recom	1.12
Target Price	107.83
Prev Close	64.79
Price	64.19
Change %	-0.93%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-26	Resumed	Goldman	Neutral	$74
Sep-08-26	Initiated	Citigroup	Buy	$108
Jul-14-26	Initiated	Stifel	Buy	$98
May-01-26	Initiated	JP Morgan	Overweight	$88
Apr-21-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$100
Jun-05-24	Initiated	Goldman	Neutral	$31
Dec-04-23	Initiated	BofA Securities	Buy	$29
Sep-19-23	Initiated	Citigroup	Neutral	$33
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform	$40
Apr-26-23	Initiated	SMBC Nikko	Outperform	$80
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform	$21 → $35
Mar-21-23	Initiated	Bernstein	Mkt Perform	$27
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$41
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform	$71 → $60
Jan-19-22	Resumed	Goldman	Buy	$90 → $85
Aug-06-21	Reiterated	Chardan Capital Markets	Buy	$97 → $94
Jun-04-21	Resumed	Robert W. Baird	Neutral	$85
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$90 → $95
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral	$75

Show Previous Ratings

Sep-29-26 07:30AM	Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies (Business Wire)
Sep-24-26 08:36PM	RNAi drug specialist ADARx raises $446M IPO (BioPharma Dive)
07:20AM	ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near (Stocktwits)
Sep-23-26 01:45AM	These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right. (Barrons.com) -6.82%
Sep-16-26 01:41PM	Not A Gangbusters Launch Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights Massive Pipeline (Stocktwits) -6.91%
03:03PM	Loading…
Sep-15-26 03:03PM	ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data Is This A Sell The News Move? (Stocktwits) -12.40%
01:13PM	FDA clears first generic radioligand drug; Sionna turns to layoffs (BioPharma Dive)
07:30AM	Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia (Business Wire)
Sep-04-26 12:13PM	This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging. (Barrons.com)
Sep-03-26 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences (Business Wire)
Aug-30-26 11:30AM	Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia (Business Wire)
Aug-24-26 07:30AM	Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress (Business Wire)
Aug-17-26 09:33AM	People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO (plozasiran) as a New Treatment Option to Reduce Triglycerides (Business Wire)
Aug-07-26 06:02AM	Significant demand for Revolution drug; Intellia pinpoints liver toxicity culprit (BioPharma Dive)
Aug-05-26 01:05AM	Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... (GuruFocus.com)
04:17PM	Loading…
Aug-04-26 04:17PM	Arrowhead Research: Fiscal Q3 Earnings Snapshot (Associated Press)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results (Business Wire)
Aug-03-26 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-27-26 07:30AM	Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia (Business Wire)
Jul-23-26 11:00AM	Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? (Trefis)
Jul-22-26 06:44PM	ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data (Stocktwits) +19.03%
05:27PM	Arrowhead Shares Soar on Strong Triglyceride Drug Data (The Wall Street Journal)
09:22AM	Why Arrowhead Shot Sky-High, While Its Chief Rival, Ionis, Toppled (Investor's Business Daily)
09:08AM	ARWR Stock On Track To Hit Over 5-Year Highs Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval (Stocktwits)
08:23AM	Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR) (InvestorsHub)
08:01AM	Arrowhead hits best-case scenario with latest results for fat-lowering drug (BioPharma Dive)
07:30AM	Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia (Business Wire)
Jul-21-26 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results (Business Wire)
Jul-14-26 11:23AM	Arrowhead gains EU authorisation for Redemplo in evolving FCS market (Clinical Trials Arena)
Jul-13-26 02:00AM	Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's? (Barrons.com)
07:35AM	Loading…
Jul-10-26 07:35AM	The Long Climb Back For Ionis Stock (Trefis) -9.05%
Jun-24-26 07:54PM	IONS Stock Jumps 4% After-Hours Goldman Sachs Lifts Price Target On Tryngolza Approval (Stocktwits)
Jun-22-26 12:33PM	Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire)
Jun-18-26 07:30AM	Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars (Business Wire)
Jun-02-26 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events (Business Wire) -5.82%
May-27-26 07:00AM	Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 (Business Wire)
May-26-26 10:00AM	Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress (Business Wire)
May-12-26 08:30AM	Wall Street's Cardiac Bet: Where Diagnostics Meet the Money (PR Newswire)
May-07-26 04:49PM	Arrowhead Research: Fiscal Q2 Earnings Snapshot (Associated Press) -6.75%
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results (Business Wire)
May-06-26 06:29AM	Arrowhead and Madrigal sign global licence for MASH RNAi therapy (Pharmaceutical Technology) +5.62%
May-05-26 11:53AM	Madrigal outlays $1bn for Arrowheads siRNA MASH asset (Pharmaceutical Technology)
08:00AM	Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals (Business Wire)
May-04-26 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events (Business Wire)
May-01-26 07:30AM	Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) (Business Wire)
Apr-24-26 10:45AM	Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings (Pharmaceutical Technology)
06:39AM	Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe (Business Wire)
Apr-21-26 10:04AM	This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains. (Barrons.com)
10:03AM	Intel upgraded, Reddit initiated: Wall Street's top analyst calls (The Fly)
Apr-20-26 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results (Business Wire)
Mar-28-26 10:30AM	Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo (Business Wire)
Mar-25-26 01:10PM	Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets (Barrons.com) +8.00%
07:03AM	Sarepta sees early success with RNAi drugs from Arrowhead (BioPharma Dive)
Mar-24-26 11:05AM	Anti-Aging Protein Research Takes a Step Forward with Cell Cloning (PR Newswire)
Mar-04-26 08:48PM	Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference (MarketBeat)
Feb-26-26 10:29AM	Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates (Zacks)
Feb-24-26 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events (Business Wire)
Feb-18-26 12:54AM	Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)'s Familial Chylomicronemia Syndrome Likely Limited (Insider Monkey)
Feb-13-26 01:45PM	CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens (Benzinga)
Feb-07-26 10:40AM	Arrowhead price target lowered to $78 from $81 at Morgan Stanley (TipRanks)
Feb-06-26 12:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... (GuruFocus.com)
Feb-05-26 08:06PM	Arrowhead Pharmaceuticals Q1 Earnings Call Highlights (MarketBeat) -5.02%
04:54PM	Arrowhead Research: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results (Business Wire)
Feb-04-26 06:15PM	Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 (PR Newswire) -5.66%
Jan-29-26 01:31PM	Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration (PR Newswire) +5.40%
Jan-27-26 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia (Business Wire)
Jan-22-26 03:20AM	Piper Sandler Highlights Arrowhead Pharmaceuticals, Inc. (ARWR) Pipeline With Upcoming Phase III Hypertriglyceridemia Data (Insider Monkey)
Jan-20-26 04:30PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results (Business Wire)
Jan-19-26 05:18PM	Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory (Insider Monkey)
Jan-12-26 05:43PM	Arrowhead Pharmaceuticals Touts Rudemplo Launch, Obesity RNAi Data and $920M Cash at JPM Conference (MarketBeat)
Jan-11-26 01:09AM	Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) (Insider Monkey)
Jan-07-26 11:05PM	Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants (Business Wire) -7.23%
07:30AM	Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China (Business Wire)
Jan-06-26 06:14PM	Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock (Business Wire) +10.85%
04:29PM	Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss (Investor's Business Daily)
11:26AM	Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay. (Barrons.com)
07:30AM	Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition (Business Wire)
Jan-05-26 07:30AM	Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire) -5.77%
Dec-23-25 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events (Business Wire)
Dec-15-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.54%
Dec-12-25 08:00AM	Arrowhead price target raised to $80 from $52 at RBC Capital (TipRanks)
Dec-08-25 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies (Business Wire) +11.65%
Dec-02-25 07:30AM	Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia (Business Wire)
Dec-01-25 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences (Business Wire) +6.74%
Nov-27-25 06:51AM	Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval (Insider Monkey)
Nov-26-25 07:16PM	Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today (Motley Fool) +23.34% -8.68%
05:47AM	Novartis cuts hundreds of jobs; Novos dual-acting diabetes drug heading to Phase 3 (BioPharma Dive)
12:00AM	Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ... (GuruFocus.com)
Nov-25-25 04:00PM	Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results (Business Wire) +5.72%
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
Nov-24-25 07:30AM	Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics (Business Wire) +9.42%
Nov-19-25 12:52PM	Arrowhead nets first commercial win as siRNA drug garners FDA approval (Pharmaceutical Technology)
Nov-18-25 11:52AM	Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire)
07:39AM	RNAi biotech Arrowhead wins first FDA approval (BioPharma Dive)
Nov-06-25 04:30PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results (Business Wire)
Nov-04-25 01:46PM	SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure (Zacks)
07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences (Business Wire)
Oct-28-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Oct-21-25 07:30AM	Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis (Business Wire)

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

PhDChristopher Richard Anzalone

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OLUKOTUN ADEOYE Y	Director	Aug 18 '26	Sale	86.96	2,000	173,920	31,600	Aug 20 05:25 PM
PERRY MICHAEL S	Director	Aug 18 '26	Sale	87.30	11,600	1,012,680	111,459	Aug 20 05:22 PM
Adeoye Olukotun	Director	Aug 18 '26	Proposed Sale	86.94	2,000	173,876		Aug 18 05:31 PM
Michael Perry	Director	Aug 18 '26	Proposed Sale	87.26	11,600	1,012,172		Aug 18 05:24 PM
Lu Hongbo	Director	May 12 '26	Sale	76.88	2,970	228,334	52,012	May 14 07:05 PM
Hongbo Lu	Officer	May 12 '26	Proposed Sale	76.87	2,970	228,299		May 12 04:35 PM
Apel Daniel Joseph	Chief Financial Officer	Apr 22 '26	Sale	71.35	13,095	934,285	162,905	Apr 24 06:44 PM
Hamilton James C	Chief Medical Officer	Apr 23 '26	Sale	75.00	10,000	750,000	226,958	Apr 24 06:38 PM
James Hamilton	Officer	Apr 23 '26	Proposed Sale	75.00	10,000	749,998		Apr 23 04:44 PM
Daniel Apel	Officer	Apr 22 '26	Proposed Sale	71.34	13,095	934,206		Apr 22 05:16 PM
Hamilton James C	Chief Medical Officer	Mar 05 '26	Sale	64.19	10,000	641,900	236,958	Mar 09 07:00 PM
James Hamilton	Officer	Mar 05 '26	Proposed Sale	64.19	10,000	641,870		Mar 05 04:49 PM
O'Brien Patrick	COO	Jan 05 '26	Sale	63.11	49,493	3,123,349	474,908	Jan 05 09:50 PM
Hamilton James C	Chief Medical Officer	Jan 05 '26	Sale	63.11	40,164	2,534,661	171,958	Jan 05 09:41 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 02 '26	Sale	66.10	13,187	871,703	3,792,739	Jan 05 09:39 PM
James Hamilton	Officer	Jan 05 '26	Proposed Sale	63.09	39,728	2,506,627		Jan 05 04:59 PM
Patrick O'Brien	Officer	Jan 05 '26	Proposed Sale	63.10	49,493	3,123,172		Jan 05 04:58 PM
Christopher Anzalone	Officer	Jan 02 '26	Proposed Sale	66.10	13,187	871,668		Jan 02 04:04 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 29 '25	Option Exercise	6.15	51,726	318,115	3,857,652	Dec 30 05:46 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 29 '25	Sale	69.13	51,726	3,575,575	3,805,926	Dec 30 05:46 PM
Ferrari Mauro	Director	Dec 26 '25	Sale	70.00	7,530	527,100	69,053	Dec 30 05:46 PM
Christopher Anzalone	Officer	Dec 29 '25	Proposed Sale	69.13	51,726	3,575,575		Dec 29 04:23 PM
Mauro Ferrari	Director	Dec 26 '25	Proposed Sale	70.00	7,530	527,070		Dec 29 04:03 PM
Waddill William D.	Director	Dec 19 '25	Sale	67.65	8,367	566,038	56,563	Dec 23 06:01 PM
Vakiener Victoria	Director	Dec 19 '25	Sale	67.68	10,040	679,491	35,723	Dec 23 06:01 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 19 '25	Sale	67.66	13,445	909,683	3,818,512	Dec 23 06:01 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 22 '25	Sale	68.44	12,586	861,340	3,805,926	Dec 23 06:01 PM
OLUKOTUN ADEOYE Y	Director	Dec 19 '25	Sale	67.66	10,000	676,623	33,600	Dec 23 06:01 PM
Christopher Anzalone	Officer	Dec 22 '25	Proposed Sale	68.43	12,586	861,319		Dec 22 04:00 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 17 '25	Sale	64.04	85,000	5,443,462	3,831,957	Dec 19 06:56 PM
Christopher Anzalone	Officer	Dec 19 '25	Proposed Sale	67.66	13,445	909,632		Dec 19 04:08 PM
William Waddill	Director	Dec 19 '25	Proposed Sale	67.65	8,367	566,001		Dec 19 04:07 PM
Adeoye Olukotun	Director	Dec 19 '25	Proposed Sale	67.66	10,000	676,589		Dec 19 04:07 PM
Victoria Vakiener	Director	Dec 19 '25	Proposed Sale	67.68	10,040	679,464		Dec 19 04:06 PM
Christopher Anzalone	Officer	Dec 17 '25	Proposed Sale	64.04	85,000	5,443,253		Dec 17 05:11 PM
Christopher Anzalone	Officer	Dec 16 '25	Proposed Sale	62.58	54,298	3,398,142		Dec 16 04:47 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 15 '25	Sale	68.85	130,000	8,950,615	3,971,255	Dec 16 01:14 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 16 '25	Sale	62.58	54,298	3,398,187	3,916,957	Dec 16 01:14 PM
Christopher Anzalone	Officer	Dec 15 '25	Proposed Sale	68.85	130,000	8,950,580		Dec 15 04:50 PM
PERRY MICHAEL S	Director	Dec 05 '25	Sale	61.03	16,250	991,738	115,240	Dec 09 06:04 PM
Michael Perry	Director	Dec 05 '25	Proposed Sale	60.99	16,250	991,129		Dec 05 04:00 PM
Ferrari Mauro	Director	Nov 28 '25	Sale	56.39	8,750	493,412	68,764	Dec 01 06:10 PM
Mauro Ferrari	Director	Nov 28 '25	Proposed Sale	56.35	8,750	493,062		Nov 28 01:19 PM

Open in Screener

ZBIO

Zenas Biopharma Inc

28.30

Oct 02 • 3:59 PM ET +0.35 (1.27%)

28.55

Aftermarket • 4:15 PM ET +0.25 (0.90%)

Healthcare Biotechnology USA Small NASD

ZBIO Zenas Biopharma Inc daily Stock Chart

Peers: RYTM KYMR VKTX BMRN CRNX INCY KRYS AXSM MDGL NBIX

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO IWC VHT

Index	RUT
Market Cap	1.84B
Enterprise Value	1.59B
Income	-484.38M
Sales	1.00M
Book/sh	3.90
Cash/sh	9.87
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	167
IPO	Sep 13, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	1844.18
P/B	7.25
P/C	2.87
P/FCF	-
EV/EBITDA	-
EV/Sales	1590.65
Quick Ratio	9.93
Current Ratio	9.93
Debt/Eq	1.58
LT Debt/Eq	1.57
Option/Short	Yes / Yes

EPS (ttm)	-9.61
EPS next Y	-5.06
EPS next Q	-1.24
EPS this Y	33.25%
EPS next Y	10.20%
EPS next 5Y	23.61%
EPS past 3/5Y	-39.47% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-127.13%
Sales Y/Y TTM	-93.33%
EPS Q/Q	-41.57%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-57.71% -93.33%

Insider Own	49.20%
Insider Trans	0.38%
Inst Own	74.92%
Inst Trans	22.69%
ROA	-97.39%
ROE	-199.04%
ROIC	-76.18%
Gross Margin	96.90%
Oper. Margin	-27390.10%
Profit Margin	-48438.40%
SMA20	-6.81%
SMA50	-9.38%
SMA200	11.94%
Trades

Shs Outstand	63.33M
Shs Float	33.11M
Short Float	35.85%
Short Ratio	16.09
Short Interest	11.87M
52W High	44.60 -36.56%
52W Low	13.50 109.59%
Volatility	6.82% 6.36%
ATR (14)	1.96
RSI (14)	41.86
Beta	-0.87
Rel Volume	2.05
Avg Volume	737.66K
Volume	1,513,616

Perf Week	4.99%
Perf Month	-14.59%
Perf Quarter	6.98%
Perf Half Y	31.85%
Perf YTD	-22.07%
Perf Year	35.06%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.25
Target Price	47.88
Prev Close	27.94
Price	28.30
Change %	1.27%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Mar-20-25	Initiated	Wedbush	Outperform	$35
Feb-04-25	Initiated	Wolfe Research	Outperform	$19
Dec-16-24	Initiated	H.C. Wainwright	Buy	$30
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$34
Oct-08-24	Initiated	Morgan Stanley	Overweight	$40
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$45
Oct-08-24	Initiated	Citigroup	Buy	$27

Sep-22-26 07:05AM	Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 (GlobeNewswire)
Sep-18-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-26 07:05AM	Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event (GlobeNewswire)
Sep-04-26 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-28-26 07:46PM	Fortune Brands and 4 More Stocks See Action From Activist Investors (Barrons.com)
04:15PM	Loading…
Aug-18-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-26 07:00AM	Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -6.68%
Jul-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.46%
Jun-11-26 04:15PM	Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit (GlobeNewswire) +11.49%
Jun-02-26 07:05PM	Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine (GlobeNewswire) -5.72%
May-28-26 07:05AM	Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD (GlobeNewswire)
May-19-26 07:05AM	Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress (GlobeNewswire) +5.50%
May-18-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.80%
May-13-26 06:50AM	Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor (GlobeNewswire)
06:00AM	Loading…
06:00AM	Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-26 12:12AM	Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million (GlobeNewswire) -17.82%
Mar-26-26 04:01PM	Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock (GlobeNewswire)
Mar-16-26 06:01PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-28-26 10:56AM	Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory (Insider Monkey)
Feb-20-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-26 07:09AM	Encouraging Phase II Trial Data Supported Zenas BioPharma, Inc. (ZBIO) in Q4 (Insider Monkey)
Feb-16-26 04:07AM	Zenas BioPharma Highlights Obexelimab Phase 3 Win, Targets Q2 BLA Filing at Guggenheim Summit (MarketBeat)
Feb-09-26 07:05AM	Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 (GlobeNewswire)
Feb-04-26 07:05AM	Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-16-26 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-10-26 09:01AM	Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Benzinga)
Jan-07-26 06:46AM	Zenas BioPharma Touts Phase 3 Win, But Stock Crashes (Benzinga) +8.62%
11:18AM	Loading…
Jan-06-26 11:18AM	ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study (Zacks) -8.49%
06:25AM	Zenas stock drops 51% despite lead assets Phase III rare disease win (Clinical Trials Arena)
Jan-05-26 04:23PM	Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. (Investor's Business Daily) -51.86%
07:05AM	Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
06:26AM	Zenas shares crash after top drug misses expectations in immune disease study (BioPharma Dive)
Dec-19-25 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +17.10%
Dec-15-25 07:05AM	Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus (GlobeNewswire) -19.71%
Dec-12-25 09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.)
Dec-03-25 07:25AM	Meridian Small Cap Growth Fund Trimmed Zenas BioPharma (ZBIO) Following Share Price Appreciation (Insider Monkey) +6.29%
Nov-12-25 07:05AM	Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-11-25 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire) +8.41%
Oct-31-25 12:41PM	How Royalty Pharma Prints Cash Without Biotech's Biggest Risks (MarketBeat)
Oct-28-25 01:34PM	1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data (MarketBeat) -5.06%
08:35AM	Zenas bifunctional mAb scores at Phase II in relapsing MS (Clinical Trials Arena)
06:00AM	Incyte trims pipeline; Zenas surges on MS drug results (BioPharma Dive)
Oct-27-25 07:05AM	Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis (GlobeNewswire) +33.08%
Oct-08-25 05:00AM	Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis (GlobeNewswire) +24.22%
Sep-02-25 07:05AM	Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million (GlobeNewswire) +9.50%
Aug-26-25 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-12-25 07:05AM	Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +6.68%
Jun-20-25 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -8.75%
Jun-02-25 04:00AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) +5.67%
May-29-25 07:05AM	Zenas BioPharma to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.34%
May-28-25 09:31AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) -12.59%
May-16-25 05:45AM	Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +7.49%
May-15-25 07:05AM	Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +12.21%
May-06-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -19.71%
May-02-25 05:45AM	Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire)
Apr-29-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +12.56%
Apr-22-25 10:37AM	Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses (GlobeNewswire)
Apr-21-25 12:33PM	Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses (GlobeNewswire) +9.30%
Apr-17-25 04:20PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.08%
Apr-07-25 03:08PM	Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (Seeking Alpha)
07:05AM	Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-20-25 02:54PM	Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress (Benzinga)
11:41AM	Zenas Bio rises as Wedbush launches with Outperform on lead asset (SeekingAlpha)
Mar-17-25 07:05AM	Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer (GlobeNewswire)
Feb-05-25 07:05AM	Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases (GlobeNewswire)
Jan-28-25 08:00AM	Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-17-24 06:25AM	Zenas BioPharma initiated with a Buy at H.C. Wainwright (TipRanks) +8.10%
Dec-12-24 07:35AM	Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley (TipRanks)
Nov-12-24 07:10AM	Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:05AM	Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
Nov-07-24 07:05AM	Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +7.63%
Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

M.B.A.Mr. Leon Oliver Moulder Jr.

COO & PresidentMr. Joseph L. Farmer

Head of Research & Development and Chief Medical OfficerDr. Lisa von Moltke M.D.

Chief Business Officer & CFOMs. Jennifer A. Fox

Chief Technical OfficerDr. Heinrich Schlieker Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zebra Aggregator, LP	Affiliate	Aug 19 '26	Proposed Sale	31.91	1,000,000	31,910,000		Aug 19 04:15 PM
MOULDER LEON O JR	Chief Executive Officer	May 18 '26	Buy	16.88	60,000	1,012,800	96,928	May 18 09:12 PM
MOULDER LEON O JR	Chief Executive Officer	Apr 29 '26	Buy	17.62	35,000	616,700	1,786,039	Apr 29 07:21 PM
MOULDER LEON O JR	Chief Executive Officer	Apr 28 '26	Buy	18.02	25,000	450,500	1,751,039	Apr 29 07:21 PM
Lu Hongbo	Director	Mar 31 '26	Buy	18.63	3,768	70,198	426,736	Apr 02 05:02 PM
Fairmount Funds Management LLC	Director	Mar 31 '26	Buy	20.00	150,000	3,000,000	2,359,025	Apr 01 04:30 PM
MOULDER LEON O JR	Chief Executive Officer	Mar 31 '26	Buy	19.31	34,000	656,540	1,726,039	Mar 31 08:14 PM
MOULDER LEON O JR	Chief Executive Officer	Mar 30 '26	Buy	18.23	20,000	364,600	1,692,039	Mar 31 08:14 PM
Lu Hongbo	Director	Mar 31 '26	Buy	20.00	75,000	1,500,000	422,968	Mar 31 05:00 PM
Lu Hongbo	Director	Feb 11 '26	Buy	22.50	25,985	584,662	347,968	Feb 13 05:35 PM
Allen Patricia L	Director	Feb 12 '26	Buy	24.85	15,700	390,088	15,700	Feb 13 05:06 PM
Allen Patricia L	Director	Feb 13 '26	Buy	26.36	4,160	109,658	19,860	Feb 13 05:06 PM
MOULDER LEON O JR	Chief Executive Officer	Feb 02 '26	Buy	17.96	57,000	1,023,720	423,155	Feb 03 04:30 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 07 '26	Buy	16.38	50,000	819,000	316,155	Jan 09 09:42 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 08 '26	Buy	16.30	30,000	489,000	346,155	Jan 09 09:42 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 09 '26	Buy	16.55	20,000	331,000	366,155	Jan 09 09:42 PM
Nunn Jason Raleigh	Director	Oct 09 '25	Buy	19.00	63,158	1,200,002	1,173,395	Oct 14 05:16 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Oct 09 '25	Buy	19.00	126,315	2,399,985	1,917,895	Oct 14 05:14 PM
ENRIGHT PATRICK G	Director	Oct 09 '25	Buy	19.00	105,265	2,000,035	1,832,669	Oct 14 08:59 AM
ENRIGHT PATRICK G	Director	Oct 09 '25	Buy	20.85	11,990	249,992	11,990	Oct 14 08:59 AM
MOULDER LEON O JR	See Remarks	Oct 07 '25	Buy	20.85	36,928	769,949	36,928	Oct 09 05:24 PM
Fairmount Funds Management LLC	Director	Oct 07 '25	Buy	19.00	316,219	6,008,161	2,209,025	Oct 09 04:15 PM
Lu Hongbo	Director	Oct 07 '25	Buy	19.00	263,160	5,000,040	321,983	Oct 09 03:37 PM

ARWR

Arrowhead Pharmaceuticals Inc

ZBIO

Zenas Biopharma Inc

Upgrade your Finviz experience